Verapamil hydrochloride: adverse event reports filed with FDA

2,547

reports as suspect product

0% of all reports · about 114 a year

156

reports, 12 months to June 2026

217 in the 12 months before

87.5%

marked serious by the reporter

87.7% across the class

29.9%

record death among outcomes, as reported

761 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Verapamil hydrochloride reports recording the termmedian drug in calcium channel blocker

1. Hypotensionlow blood pressure11.9%304
2. Drug interactionan interaction between medicines10.6%269
3. Nauseafeeling sick10.5%267
4. Completed suicidedeath by suicide10.1%258
5. Dyspnoeashortness of breath9.8%250
6. Bradycardiaslow heart rate9.1%232
7. Off label useused for a purpose or in a way not on the label9%228
8. Dizzinesslight-headedness or unsteadiness8.8%224
9. Toxicity to various agentspoisoning or toxic effect of one or more substances8.6%219
10. Abdominal painstomach or belly pain7.9%202
11. Diarrhoealoose or frequent stools7.9%200
12. Coma7.8%199
13. Drug ineffectivethe medicine did not work as expected7.8%198
14. Headachehead pain7.3%186
15. Tachycardiafast heart rate7.3%186
16. Fatiguetiredness7.2%183
17. Cardio-respiratory arrestthe heart and breathing stopped7.1%181
18. Coughcough7.1%181
19. Vomitingbeing sick7%178
20. Pruritusitching6.7%171
21. Falla fall6.7%170
22. Astheniaweakness or lack of energy6.6%169
23. Blood pressure increaseda raised blood pressure reading6.4%162
24. Arthralgiajoint pain6.2%159
25. Haemorrhagic stroke6.1%156
26. Sepsisa severe body-wide response to infection6.1%156
27. Head discomfortdiscomfort in the head5.9%151
28. Somnolencedrowsiness5.9%151
29. Chillschills or shivering5.8%147
30. Altered state of consciousness5.7%145

Top 30 of 593 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 6 drugs in the calcium channel blocker class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 76,049 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 44.6% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 2,547 reports.

Drugs most often listed in the same reports

Other products listed in reports where Verapamil hydrochloride is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the calcium channel blocker class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Verapamil hydrochloride as a suspect or interacting product; reports listing it only as a concomitant medication (2,107) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.